Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ronald Harris

Hematology & Oncology Johnson City, NY Doctor of Osteopathy

NPI 1447249099 CMS profile 110977

30 Harrison St, Suite 100, Johnson City, NY 13790

Open in the dashboard

General payments

$6,331

367 records reported · program years 2019–2025

Research payments

$20,105

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,928,328 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Ronald Harris of Johnson City, NY is reported in the CMS Open Payments database as having received $6,331 across 367 general payments and $20,105 in research payments paid to them. Separately, studies naming them as principal investigator received $1,928,328 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,226 64
2024 General $1,689 106
2024 Research $20,105 2
2023 General $919 50
2022 General $905 46
2021 General $453 24
2020 General $285 18
2019 General $852 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronald Harris
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Ronald Harris were reported at $1,226. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Ronald Harris Hematology & Oncology median Middle half National median
2019 $852 $529 $121–$2,516 $163
2020 $285 $339 $82–$2,213 $114
2021 $453 $263 $49–$1,965 $132
2022 $905 $416 $103–$2,395 $149
2023 $919 $542 $125–$2,646 $160
2024 $1,689 $692 $141–$3,008 $164
2025 $1,226 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $664 42 payments
  2. Pfizer Inc. $545 41 payments
  3. E.R. Squibb & Sons, L.L.C. $519 32 payments
  4. AbbVie, Inc. $420 22 payments
  5. Celgene Corporation $309 22 payments
  6. AstraZeneca Pharmaceuticals LP $281 16 payments
  7. Janssen Biotech, Inc. $249 15 payments
  8. Genentech USA, Inc. $219 14 payments
  9. Incyte Corporation $189 5 payments
  10. PharmaEssentia USA Corporation $174 9 payments
  11. Other $2,762 149 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,165 362 payments
  2. Education $166 5 payments
Products named General payments · program years 2019–2025
  1. OPDIVO $425 23 payments
  2. IMBRUVICA $325 16 payments
  3. BOSULIF $268 22 payments
  4. EPKINLY $222 11 payments
  5. REBLOZYL $190 15 payments
  6. MONJUVI $176 4 payments
  7. BESREMI $174 9 payments
  8. SCEMBLIX $160 8 payments
  9. KISQALI $134 10 payments
  10. INLYTA $132 8 payments
  11. Other $5,466 324 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $20,105 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

1,137

Median for Hematology-Oncology: 604

Drug cost

$2,641,410

Median for Hematology-Oncology: $1,306,514

Branded share of claims

31%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Imbruvica Ibrutinib Brand 38 $588,102
Jakafi Ruxolitinib Phosphate Brand 24 $431,573
Ibrance Palbociclib Brand 23 $347,497
Cabometyx Cabozantinib S-Malate Brand 11 $264,547
Xtandi Enzalutamide Brand 18 $200,702
Verzenio Abemaciclib Brand 11 $162,161
Calquence Acalabrutinib Maleate Brand 11 $160,598
Neupogen Filgrastim Brand 12 $141,007
Rubraca Rucaparib Camsylate Brand 12 $106,301
Eliquis Apixaban Brand 76 $75,744

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$65,458

Medicare's payments for the services billed

Medicare patients

405

Average age 74

Services billed

869

239 women, 166 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Cancer 50%
Diabetes 33%
Chronic kidney disease 27%
Ischemic heart disease 25%
COPD 24%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 55 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REBLOZYL
  • Celgene Corporation $149
$149 — —
BESREMI
  • PharmaEssentia USA Corporation $95
$95 — —
IMBRUVICA
  • AbbVie, Inc. $83
$83 38 —
SCEMBLIX
  • Novartis Pharmaceuticals Corporation $71
$71 — —
ENHERTU
  • AstraZeneca Pharmaceuticals LP $50
  • Daiichi Sankyo Inc. $17
$67 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 55 with Patron

Records

369 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record